Pulmatrix doses first patient in Ph1 Pulmazole trial

Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole. The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Related Links:

ABSTRACT The study of the human microbiome-and, more recently, that of the respiratory system-by means of sophisticated molecular biology techniques, has revealed the immense diversity of microbial colonization in humans, in human health, and in various diseases. Apparently, contrary to what has been believed, there can be nonpathogenic colonization of the lungs by microorganisms such as bacteria, fungi, and viruses. Although this physiological lung microbiome presents low colony density, it presents high diversity. However, some pathological conditions lead to a loss of that diversity, with increasing concentrations of so...
Source: Jornal Brasileiro de Pneumologia - Category: Respiratory Medicine Source Type: research
Publication date: Available online 24 November 2018Source: Respiratory Medicine Case ReportsAuthor(s): Shuko Hirota, Yoichi Kobayashi, Takashi Ishiguro, Takashi Nishida, Naho Kagiyama, Yoshihiko Shimizu, Noboru TakayanagiAbstractA 56-year-old woman was referred to our hospital for recurrent asthma of 20 years duration. She was diagnosed as having allergic bronchopulmonary aspergillosis on the basis of clinical symptoms, peripheral blood eosinophilia, elevated total serum immunoglobulin E value, positive results of specific IgE and precipitating antibodies against Aspergillus sp., central bronchiectasis, and mucoid impactio...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Conditions:   Aspergillosis;   Asthma Interventions:   Drug: PC945;   Drug: Placebo Sponsor:   Pulmocide Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Conclusions: In adult pts with CF and ASA/ABPA OM treated decrease PE and oral antibiotics use suggesting that anti IgE therapy may play a role in improving clinical outcomes in this subset of CF pts.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Cystic fibrosis Source Type: research
In conclusion, a non-negligible proportion of patients with nonspecific alterations of screening tests at baseline may develop Aspergillus-associated syndromes during follow-up. Future studies are needed to confirm our observations.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections Source Type: research
Conclusion: Post-tuberculosis bronchiectasis is a common sequela in a high burden TB country and coexistent CPA may arise and should be considered, especially in smear negative patients suspected for TB reactivation.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Tuberculosis Source Type: research
Conclusion: Our study demonstrates the difficulty in applying the ISHAM criteria to historic cohorts and our results are similar to the study by Page et al(2). The ISHAM criteria are a huge step in standardising the diagnosis of ABPA for future clinical and research studies. Obligatory Criterian=111Total IgE>1000 IU/ml79(71%)+ve Af IgE108(97%)Both obligatory criteria fulfilled79(71%)Full diagnostic criteria fulfilled73(66%)‘Other’ CriteriaRaised Af IgG/+ve precipitins94(85%)Eosinophil>500/uL97(87%)Radiological features of ABPA101(91%)‘Other’ criteria combinations1 ‘other’ criterion...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Allergy and immunology Source Type: research
Introduction: Allergic Bronchopulmonary Aspergillosis(ABPA) most commonly presents with poorly controlled asthma &wheezing. Radiological features include central bronchiectasis &mucus impaction of airways.ABPA presenting as lobar collapse is relatively uncommon.Aim: To study clinical and radiological features of patients with ABPA(non-CF) presenting with lobar collapse.Method: A retrospective analysis of case records of patients diagnosed with ABPA from 2007-2017 at NNUH was done. Clinic letters, radiographic images and laboratory test records were reviewed.Results: A total of 10 patients were identified(n=111,9%)....
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Clinical Problems Source Type: research
Conclusion: We demonstrated time trends in the clinical characteristics of patients with severe asthma and their comorbidities in the BSAR, which might be influenced by the availability of novel biologics.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Clinical Problems Source Type: research
More News: Allergy & Immunology | Aspergillosis | Asthma | Clinical Trials | Respiratory Medicine | Study